Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases
Tharmala Tharmalingam, Xiaobing Han, Ashley Wozniak, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 18, Iss. 2
Open Access | Times Cited: 23

Showing 23 citing articles:

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 31
A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection
Wanbo Tai, Kai Yang, Yubin Liu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 15
Prevention of Congenital Cytomegalovirus Infection: Review and Case Series of Valaciclovir versus Hyperimmune Globulin Therapy
Gerardo Nigro, Mario Muselli
Viruses (2023) Vol. 15, Iss. 6, pp. 1376-1376
Open Access | Times Cited: 12
Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?
Abdul Hawil Abas, Siti Marfuah, Rinaldi Idroes, et al.
Molecules (2022) Vol. 27, Iss. 7, pp. 2221-2221
Open Access | Times Cited: 19
Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?
Coco R. Beudeker, Daniel C. Vijlbrief, Joris M. van Montfrans, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Transchromosomic bovines‐derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS‐CoV‐2, MERS‐CoV, Ebola, Zika, HIV‐1, and influenza A virus
AbdulRahman A. Saied, Manuela Sales Lima Nascimento, Adriano Henrique do Nascimento Rangel, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 10, pp. 4599-4610
Open Access | Times Cited: 10
Passive Transfer of Animal-Derived Polyclonal Hyperimmune Antibodies Provides Protection of Mice from Lethal Lassa Virus Infection
Lisa Oestereich, Helena Müller-Kräuter, Elisa Pallasch, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1436-1436
Open Access | Times Cited: 5
SIR+ models: accounting for interaction-dependent disease susceptibility in the planning of public health interventions
Maria M. Martignoni, Aura Raulo, Omer Linkovski, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase
Kevin E. Ramos, Nisreen M.A. Okba, Jessica Tan, et al.
mBio (2024) Vol. 15, Iss. 7
Open Access | Times Cited: 1
Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography
Julie M. Fox, Vicky Roy, Bronwyn M. Gunn, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Neutralization Of SARS-CoV-2 Variants By A Human Polyclonal Antibody Therapeutic (COVID-HIG, NP-028) With High Neutralizing Titers To SARS-CoV-2
Derek Toth
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
Hyperimmune Targeting Staphylococcal Toxins Effectively Protect Against USA 300 MRSA Infection in Mouse Bacteremia and Pneumonia Models
Xiaobing Han, Roger V. Ortines, Ipsita Mukherjee, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 4
Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection
Aruni Jha, Douglas C. Barker, J. Lew, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 4
A Comparison of Polyvalent Passive Immunoprotection from Antibodies with Different Immunity Models of Live or Inactivated Vibrio fluvialis in Fish
Huihui Xiao, Pan Cui, Jing Chen, et al.
Fishes (2024) Vol. 9, Iss. 8, pp. 302-302
Open Access
Different drugs used as therapeutic targets against AD till date
Manisha Nahar, Aamir Khan, Ravina Rai, et al.
Elsevier eBooks (2024), pp. 191-216
Closed Access
Rising anti-SARS-CoV-2 titer in a human immunoglobulin preparation
Matthias Germer, Viola Marschall, Veit Braun, et al.
International Journal of Blood Transfusion and Immunohematology (2023) Vol. 13, Iss. 1, pp. 1-8
Open Access | Times Cited: 1
Comparison of neutralization potency across passive immunotherapy approaches as potential treatments for emerging infectious diseases
Hossein Ranjbaran, Yahya Ehteshaminia, Mohammadreza Nadernezhad, et al.
Heliyon (2023) Vol. 10, Iss. 1, pp. e23478-e23478
Open Access | Times Cited: 1
Development, Histological, and Ultrastructural Evaluation of Sheep Hyperimmune Serum Therapy for COVID-19
Elif Demirci, E Yilmaz, Engin Alp Onen
International Journal of Morphology (2023) Vol. 41, Iss. 6, pp. 1687-1697
Open Access | Times Cited: 1
Hyperimmunplasma: Gewinnung, Verarbeitung und therapeutische Anwendungen
Gabriele Niemann, Matthias Germer, Matthias Hauf, et al.
Transfusionsmedizin (2023) Vol. 13, Iss. 01, pp. 18-29
Closed Access
Equine Polyclonal Antibodies Prevent Acute Chikungunya Virus Infection in Mice
Douglas Barker, Xiaobing Han, Eryu Wang, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1479-1479
Open Access
Preventive antibody products are immunizations
Richard Hughes, Spreeha Choudhury
Vaccine (2023) Vol. 41, Iss. 48, pp. 7041-7043
Closed Access
Special focus issue: passive immunization
Larry Zeitlin, Richard A. Cone
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 2
Open Access
Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy?
Francisco López‐Medrano, José María Aguado
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 10, pp. 1386-1388
Open Access
Page 1

Scroll to top